Management Team

Meet our Management Team

Greg West CA

Chief Executive Officer

Greg West has been our Chief Executive Officer since August 2016 and, prior to that was Interim Chief Executive Officer from December 2015. He was also our Chief Financial Officer and Company Secretary from May 2011 until August 2016.. From May 2010 to January 2011, he was Chief Financial Officer at Immune Systems Therapeutics, Ltd., a medical diagnostic company. Mr. West is a Chartered Accountant. He is a Director and Audit Committee Chairman of each of UOWD Limited (a business arm of Wollongong University) and IDP Education Limited and Education Australia Limited. He worked at Pricewaterhouse Coopers and has held finance executive roles with financial institutions, including BT Financial Group, Deutsche Bank AG and IAG New Zealand

Cliff Holloway, BPharm, PhD

Chief Business and Operations Officer

Dr Cliff Holloway brings over 25 years of biopharmaceutical and healthcare related experience to Benitec, in the development and commercialisation of emerging technologies and drug products, including licensing, M&A, corporate financing, and operations management. Most recently, he was CEO and Managing Director of Sienna Cancer Diagnostics Ltd. . Prior to his role at Sienna, he held the position of Managing Director at Immune System Therapeutics Ltd. and also for Biosceptre International Ltd. and was formerly VP of Business Development at Arana Therapeutics Ltd. which was acquired by US based Cephalon Inc. (now Teva) in 2009. He is currently a director of a biotech focused seed fund, Newstar Ventures.

Cliff holds a Bachelor of Pharmacy and a PhD in Medicinal Chemistry from the University of Nottingham, UK.

David Suhy, BSc PhD

Chief Scientific Officer

David Suhy was appointed as our Chief Scientific Officer in April 2015, prior to which he served as our Senior Vice President, Research & Development since October 2012. In April 2008, he joined Tacere Therapeutics, Inc. as Director of Research & Development and continued in that role until our acquisition of Tacere in October 2012. Previous roles include Associate Director of R&D at Clontech Laboratories, Inc. and Principal Scientist at Antara Biosciences Inc. He also led the Target Validation Group at PPD Discovery, a company with proprietary technology surrounding the use of genetic suppressor elements to identify “druggable” genomic targets for large pharmaceutical companies. Dr Suhy holds a BS in Biochemistry and Biophysics from the University of Pittsburgh, earned his PhD in Biochemistry, Molecular Biology and Cell Biology at Northwestern University, and conducted his post-doctoral work at Stanford

Bryan Dulhunty

Chief Financial Officer

Bryan brings a unique set of skills and experience to life science companies. Bryan is a qualified Chartered Accountant who has been heavily involved in the life science industry for nearly 20 years. His previous roles cover positions such as Executive Chairman, Managing Director, CEO, Company Secretary and CFO of numerous listed and non listed life science companies.

​Educated at Sydney University (Economics degree), Bryan became a Chartered Accountant while working with Ernst and Young while maintaining a strong interest in science.

Bryan then made the move to the commercial world by joining one of the worlds largest multinational companies. Wanting to have a greater input on decision making, Bryan entered the world of Australian small start up companies.

Bryan’s passion lay with life science, hence the formation of CoSA in 2000. Bryan soon developed an extensive client base including being invited to become a director of a number of listed and unlisted public companies.

In 2005 Bryan was invited to take on the role of Executive Chairman to restructure a listed biotech with significant governance issues. Over the next 7 years under Bryan’s leadership the Company prospered. Its research was developed from the pre-clinical stage to FDA approved Phase II trials in the USA.  Bryan’s involvement with the Company ended in mid 2012 leaving it with a strong cash position having raised over $40m, a strong patent position, strong product development plan and the strong support of shareholders.

Bryan re-established CoSA as a boutique service provider to the life science community bringing a unique and broad set of skills and experien

Georgina Kilfoil, BSc, MBA, PMP

Chief Clinical and Development Operations Officer

Georgina Kilfoil was appointed as our Chief Clinical and Development Operations Officer in April 2016 prior to which she served as Chief Clinical Officer since April 2015. Ms Kilfoil joined Benitec in February 2015 as Vice President, Clinical Operations. Prior to joining Benitec, Ms. Kilfoil was a business consultant from March 2013 to December 2014 and prior to that was Senior Vice President, Project Management at Anthera Pharmaceuticals, Inc. from March 2010 to February 2013. Previous to this, Ms. Kilfoil served as Project Management Consultant at InClin, Inc. and Vice President of Project Management at Peninsula Pharmaceuticals, Inc. Ms. Kilfoil is a certified Project Management Professional, has a Bachelor of Science Degree in Pharmacology from the University of Bristol, United Kingdom, and a Masters of Business Administration from the Australian Graduate School of Management, Sydney, Australia.

Michael Graham, BSc (Hons), PhD

Founding Scientist & Head of Discovery

Dr Graham’s research interests are in the field of molecular genetics, with a particular focus on the applications of RNAi in biotechnology. He commenced the development of Benitec’s ddRNAi technology while working in plant biotechnology at CSIRO and continued this work at QDPI and Benitec, focusing on medical applications; the core Benitec patent portfolio was developed at this time. Following Benitec’s restructure Dr Graham moved to the University of Queensland where he worked on developing applications of RNAi in plant biotechnology in an industry collaborative program. In January 2012 Dr Graham re-joined Benitec Biopharma as Chief Scientist and oversees the development of Benitec Biopharma’s scientific programs. In June 2015, Dr Graham was appointed Founding Scientists & Head of Discovery. He has re-located to the USA, working at Benitec’s Laboratory, where he will focus on new technologies.

Greg West CA

Chief Executive Officer

Greg West has been our Chief Executive Officer since August 2016 and, prior to that was Interim Chief Executive Officer from December 2015. He was also our Chief Financial Officer and Company Secretary from May 2011 until August 2016.. From May 2010 to January 2011, he was Chief Financial Officer at Immune Systems Therapeutics, Ltd., a medical diagnostic company. Mr. West is a Chartered Accountant. He is a Director and Audit Committee Chairman of each of UOWD Limited (a business arm of Wollongong University) and IDP Education Limited and Education Australia Limited. He worked at Pricewaterhouse Coopers and has held finance executive roles with financial institutions, including BT Financial Group, Deutsche Bank AG and IAG New Zealand

Cliff Holloway, BPharm, PhD

Chief Business and Operations Officer

Dr Cliff Holloway brings over 25 years of biopharmaceutical and healthcare related experience to Benitec, in the development and commercialisation of emerging technologies and drug products, including licensing, M&A, corporate financing, and operations management. Most recently, he was CEO and Managing Director of Sienna Cancer Diagnostics Ltd. . Prior to his role at Sienna, he held the position of Managing Director at Immune System Therapeutics Ltd. and also for Biosceptre International Ltd. and was formerly VP of Business Development at Arana Therapeutics Ltd. which was acquired by US based Cephalon Inc. (now Teva) in 2009. He is currently a director of a biotech focused seed fund, Newstar Ventures.

Cliff holds a Bachelor of Pharmacy and a PhD in Medicinal Chemistry from the University of Nottingham, UK.

David Suhy, BSc PhD

Chief Scientific Officer

David Suhy was appointed as our Chief Scientific Officer in April 2015, prior to which he served as our Senior Vice President, Research & Development since October 2012. In April 2008, he joined Tacere Therapeutics, Inc. as Director of Research & Development and continued in that role until our acquisition of Tacere in October 2012. Previous roles include Associate Director of R&D at Clontech Laboratories, Inc. and Principal Scientist at Antara Biosciences Inc. He also led the Target Validation Group at PPD Discovery, a company with proprietary technology surrounding the use of genetic suppressor elements to identify “druggable” genomic targets for large pharmaceutical companies. Dr Suhy holds a BS in Biochemistry and Biophysics from the University of Pittsburgh, earned his PhD in Biochemistry, Molecular Biology and Cell Biology at Northwestern University, and conducted his post-doctoral work at Stanford

Bryan Dulhunty

Chief Financial Officer

Bryan brings a unique set of skills and experience to life science companies. Bryan is a qualified Chartered Accountant who has been heavily involved in the life science industry for nearly 20 years. His previous roles cover positions such as Executive Chairman, Managing Director, CEO, Company Secretary and CFO of numerous listed and non listed life science companies.

​Educated at Sydney University (Economics degree), Bryan became a Chartered Accountant while working with Ernst and Young while maintaining a strong interest in science.

Bryan then made the move to the commercial world by joining one of the worlds largest multinational companies. Wanting to have a greater input on decision making, Bryan entered the world of Australian small start up companies.

Bryan’s passion lay with life science, hence the formation of CoSA in 2000. Bryan soon developed an extensive client base including being invited to become a director of a number of listed and unlisted public companies.

In 2005 Bryan was invited to take on the role of Executive Chairman to restructure a listed biotech with significant governance issues. Over the next 7 years under Bryan’s leadership the Company prospered. Its research was developed from the pre-clinical stage to FDA approved Phase II trials in the USA.  Bryan’s involvement with the Company ended in mid 2012 leaving it with a strong cash position having raised over $40m, a strong patent position, strong product development plan and the strong support of shareholders.

Bryan re-established CoSA as a boutique service provider to the life science community bringing a unique and broad set of skills and experien

Georgina Kilfoil, BSc, MBA, PMP

Chief Clinical and Development Operations Officer

Georgina Kilfoil was appointed as our Chief Clinical and Development Operations Officer in April 2016 prior to which she served as Chief Clinical Officer since April 2015. Ms Kilfoil joined Benitec in February 2015 as Vice President, Clinical Operations. Prior to joining Benitec, Ms. Kilfoil was a business consultant from March 2013 to December 2014 and prior to that was Senior Vice President, Project Management at Anthera Pharmaceuticals, Inc. from March 2010 to February 2013. Previous to this, Ms. Kilfoil served as Project Management Consultant at InClin, Inc. and Vice President of Project Management at Peninsula Pharmaceuticals, Inc. Ms. Kilfoil is a certified Project Management Professional, has a Bachelor of Science Degree in Pharmacology from the University of Bristol, United Kingdom, and a Masters of Business Administration from the Australian Graduate School of Management, Sydney, Australia.

Michael Graham, BSc (Hons), PhD

Founding Scientist & Head of Discovery

Dr Graham’s research interests are in the field of molecular genetics, with a particular focus on the applications of RNAi in biotechnology. He commenced the development of Benitec’s ddRNAi technology while working in plant biotechnology at CSIRO and continued this work at QDPI and Benitec, focusing on medical applications; the core Benitec patent portfolio was developed at this time. Following Benitec’s restructure Dr Graham moved to the University of Queensland where he worked on developing applications of RNAi in plant biotechnology in an industry collaborative program. In January 2012 Dr Graham re-joined Benitec Biopharma as Chief Scientist and oversees the development of Benitec Biopharma’s scientific programs. In June 2015, Dr Graham was appointed Founding Scientists & Head of Discovery. He has re-located to the USA, working at Benitec’s Laboratory, where he will focus on new technologies.

Stay updated today

Keep up with programs, reports, announcements and events.

Sign Up